JAKi Safety and Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years Now in the RheumNow poster hall: Long-term extension outcomes from SELECT-BEYOND through 5 years in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs. https://t.co/xltJjADdHz https://t.co/sytZLayxDZ

• Safety and Efficacy of a JAKi in Patients with Rheumatoid Arthritis and Inadequ…

Registration is now open! Early bird pricing is available until 11/30/23. See you there! https://t.co/zEf9KTXYqX https://t.co/eQTQzgJpVF

• RN Live - RheumNow

The frequency of demyelinating Dz (DD) studied in 2260 #SpA pts, finging 18 DD events (IR 31 per 100K PYs) DD at 20 yrs was higher in axSpA than PsA (1.30 vs 0.13%, p= 0.01). DD risk w/ smoking (HR 2.9), axSpA (8.8) & IBD (5.7) -- NOT TNFi! https://t.co/IVoCxd6H0D https://t.co/FQtHuUWYUx

• Incidence and predictors of demyelinating disease in spondyloarthritis: data fr…

QD Clinic: Steroid Response for a #PMR Diagnosis Featuring Dr. Jack Cush (Dallas, TX): Exquisite response to prednisone but other red flags! https://t.co/DCtcZqG5NE https://t.co/Rs9rfds5w0

• QD Clinic: Steroid Response for a PMR Diagnosis | RheumNow

TNR: #PMR Diagnosis and Monitoring Tuesday Night Rheumatology webinar on the diagnosis and monitoring of PMR. Featuring Panelists, Drs. Claire Owen, Anisha Dua, Stephen Paget and moderated by Jack Cush. https://t.co/7ewWLAUf4N @anisha_dua @Rheummd @drceowen https://t.co/GCtYUHBPba

• TNR: PMR Diagnosis and Monitoring | RheumNow

Multinational study of 47 studies of 11,085 #RA pts showed the prevalence of ANXIETY to range from 2.4% to 77%. Variance due to inconsistent, non-standardized self-report measures and clinical thresholds. Common; but how common? https://t.co/elcxjfSI7N https://t.co/iRNeQy4pEk

• Prevalence, Severity and Measures of Anxiety in Rheumatoid Arthritis: A Systema…

Network metanalysis review of 65 trials (n=5957) looked at Tx effect in Hand #OA. Whereas oral NSAIDs & glucocorticoids’ NMA were effective compared with placebo; intraarticular steroid & hyaluronate, and HCQ and topical NSAIDs were NOT. https://t.co/8CCkfWd80E https://t.co/jpqlq8Xwgp

• Comparative effectiveness of pharmacological interventions for hand osteoarthri…

QD Clinic: Difficult #PMR Considerations Featuring Dr. Sarah Mackie (Leeds, UK) Difficulty weaning prednisone leads to consideration of other confounders and conditions QD Clinics are video vignettes with lessons from the clinic. https://t.co/H6cZaMperr @Sarah_L_Mackie https://t.co/WtCX6xfWe3

• QD Clinic: Difficult PMR Considerations | RheumNow

Gout Flare Prophylaxis - Colchicine or NSAIDs? A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout. https://t.co/MfVvBy0DsD https://t.co/jP5oiAHaBa

• Gout Flare Prophylaxis - Colchicine or NSAIDs? | RheumNow

Subclinical vasculitis in PMR For a long time #PMR has been an underinvestigated disease. This is changing with new possibilities to make a more accurate diagnosis with imaging as well as new therapies for treatment resistant disease. https://t.co/t0BRosgMWt https://t.co/bWZzRidqlm

• Subclinical vasculitis in polymyalgia rheumatica | RheumNow

Subclinical GCA prevalence in newly Dx #PMR ranges from 23 to 29%; best by Vessel imaging or temporal artery Bx. #PMR & GCA share common genetic/pathogenic inflammatory mechanisms & an IL-6 signature; BUT there are differences; further research needed! https://t.co/MhuIs068NG https://t.co/1BeeP3RY0H

• Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditio…